Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Articles

Pages

173330 items
9:44 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Histogenics' NeoCart misses in Phase III for knee cartilage repair

Histogenics Corp. (NASDAQ:HSGX) said NeoCart missed the primary endpoint of improving pain and function at one year in a Phase III trial to repair knee cartilage damage. The company said the product narrowly missed the...
9:43 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Other News

Clovis settling SEC complaint for $20M

The SEC said Clovis Oncology Inc. (NASDAQ:CLVS) will pay more than $20 million in penalties to settle charges that it misled investors about the efficacy of discontinued lung cancer candidate rociletinib. According to SEC's complaint, Clovis...
9:43 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Atomwise identifying small molecules for Pfizer

Atomwise Inc. (San Francisco, Calif.) partnered with Pfizer Inc. (NYSE:PFE) to use its AI platform to identify small molecule candidates for up to three target proteins from Pfizer. Atomwise will receive an undisclosed technology access...
9:43 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
9:42 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

BioCryst's oral HAE candidate reduces attack symptom severity in Phase II

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) reported data from 33 evaluable patients treated for a total of 95 acute attacks of hereditary angioedema (HAE) in the Phase II ZENITH-1 trial showing that a single 750 mg dose...
9:42 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

AZ says Phase IIIb data of Bevespi Aerosphere in COPD are 'inconsistent with previous data'

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Bevespi Aerosphere glycopyrrolate/formoterol fumarate met one of three primary endpoints in the Phase IIIb AERISTO trial to treat moderate to very severe chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere was...
9:42 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Nucleix's Lung EpiCheck detects lung cancer with 91% specificity, 74% sensitivity

Nucleix Ltd. (Rehovot, Israel) said its Lung EpiCheck blood test showed 91% specificity and 74% sensitivity for the early detection of lung cancer in a cohort of 181 lung cancer patients and 141 current or...
9:42 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Filgotinib meets in Phase II for ankylosing spondylitis

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported that once-daily 200 mg oral filgotinib met the primary endpoint of reducing mean Ankylosing Spondylitis Disease Activity Score (ASDAS) from baseline to week 12 vs....
9:41 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Progenics' prostate cancer imaging agent meets specificity endpoint in Phase III

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said SPECT/CT imaging with its 99mTc-MIP-1404 (1404, F-1311) imaging agent met the co-primary endpoint of specificity but missed the co-primary endpoint of sensitivity in a Phase III trial to detect low-grade...
9:39 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Viking's VK2809 meets in Phase II for NAFLD

Viking Therapeutics Inc. (NASDAQ:VKTX) reported that VK2809 met the primary and secondary endpoints in a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD). The company plans to meet with FDA early next year...

Pages